BioStock: Curasight’s rights issue subscription period has commenced
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

•Tips: Så får du försprång när du handlar med amerikanska aktier (annons)

Pressmeddelande

BioStock: Curasight’s rights issue subscription period has commenced

Cision Publicerad: 06 May 14:28
Curasight

Curasight is currently conducting a DKK 100 million rights issue, with the subscription period closing on May 16. Having secured DKK 47 million in pre-subscriptions and guarantees, plus a DKK 18 million renegotiated loan facility, the company aims to advance in parallel its uTRACE diagnostic and uTREAT therapeutic platforms for cancers such as prostate cancer and glioblastoma.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/curasights-rights-issue-subscription-period-has-commenced/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Curasight

Läses av andra just nu

Om aktien Curasight

Senaste nytt